Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Paul Haas

Clinical Cardiac Electrophysiology Phoenix, AZ Medical Doctor

NPI 1124249560 CMS profile 6019

9201 W Thomas Rd, Phoenix, AZ 85037

Open in the dashboard

General payments

$136,215

450 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Paul Haas of Phoenix, AZ is reported in the CMS Open Payments database as having received $136,215 across 450 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $37,716 81
2024 General $10,461 68
2023 General $13,798 66
2022 General $11,064 55
2021 General $3,756 51
2020 General $9,011 27
2019 General $50,409 102

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Paul Haas
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to Paul Haas were reported at $37,716. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year Paul Haas Clinical Cardiac Electrophysiology median Middle half National median
2019 $50,409 $2,361 $585–$8,260 $163
2020 $9,011 $993 $247–$4,351 $114
2021 $3,756 $1,185 $326–$4,739 $132
2022 $11,064 $2,073 $554–$6,789 $149
2023 $13,798 $2,568 $759–$8,159 $160
2024 $10,461 $2,557 $703–$7,403 $164
2025 $37,716 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $63,657 143 payments
  2. Biosense Webster, Inc. $38,411 83 payments
  3. Boston Scientific Corporation $27,235 70 payments
  4. Medtronic, Inc. $3,303 39 payments
  5. Philips Electronics North America Corporation $873 5 payments
  6. Medtronic Vascular, Inc. $728 10 payments
  7. Cardiva Medical, Inc. $563 46 payments
  8. Impulse Dynamics (USA) Inc. $338 5 payments
  9. Janssen Pharmaceuticals, Inc $174 4 payments
  10. Amgen Inc. $123 2 payments
  11. Other $809 43 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $80,282 82 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $22,925 11 payments
  3. Food and Beverage $14,953 307 payments
  4. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $9,202 9 payments
  5. Travel and Lodging $8,787 38 payments
  6. Education $67 3 payments
Products named General payments · program years 2019–2025
  1. Ensite Cardiac Mapping System $39,627 49 payments
  2. Carto 3 $36,689 65 payments
  3. WATCHMAN Access System $21,633 12 payments
  4. Engage Standard Introducer $7,490 9 payments
  5. Quadra Allure MP RF CRT Pacemkr $3,745 6 payments
  6. ADVISOR $2,350 2 payments
  7. Allure CRT Pacemaker $1,926 4 payments
  8. Micra $1,883 23 payments
  9. Quadra Assura CRT Defibrillator $1,464 5 payments
  10. EnSite Precision Cardiac Mapping System $1,101 8 payments
  11. Other $16,400 254 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 39 drugs

Part D claims

2,865

Median for Clinical Cardiac Electrophysiology: 1,090

Drug cost

$594,608

Median for Clinical Cardiac Electrophysiology: $354,841

Branded share of claims

37.9%

Median for Clinical Cardiac Electrophysiology: 38.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 360 $423,951
Xarelto Rivaroxaban Brand 94 $91,242
Entresto Sacubitril/Valsartan Brand 25 $22,388
Flecainide Acetate Generic 411 $21,019
Sotalol Sotalol Hcl Brand 282 $5,858
Metoprolol Succinate Generic 262 $4,081
Diltiazem 24hr Er (Cd) Diltiazem Hcl Brand 82 $2,266
Propafenone Hcl Er Propafenone Hcl Brand 12 $1,883
Dofetilide Generic 15 $1,644
Amiodarone Hcl Generic 77 $1,432

The 10 drugs with the highest cost, of 39 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,573 Part D prescribers listed as Clinical Cardiac Electrophysiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 94 billing codes

Paid by Medicare

$607,408

Of which drugs: $213

Medicare patients

1,054

Average age 77

Services billed

8,846

466 women, 588 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 73%
Arthritis 56%
Ischemic heart disease 50%
Heart failure 46%
Chronic kidney disease 46%
Diabetes 32%
COPD 24%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 12 48 $203

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LEQVIO
  • Novartis Pharmaceuticals Corporation $25
$25 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

450 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Cardiac Electrophysiology in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record